A26 Informational Reports: Insights for Pharma Stakeholders
Explore key findings from the AMA's A26 Informational Reports, highlighting grants, corporate relationships, and public health strategies.
- Publisher
- American Mediacal Association
- Length
- 150 pages
- File
- 0 B PDF
Why this matters
Total grants and donations received by the AMA in 2025 amounted to $3,666,000, supporting various public health initiatives.
Executive summary
- Total grants and donations received by the AMA in 2025 amounted to $3,666,000, supporting various public health initiatives.
- The AMA approved 105 corporate activities in 2025, emphasizing collaboration and compliance with established guidelines.
- Key focus areas for the AMA include public health, tobacco control, and Medicare payment reform.
AI research brief
Explore key findings from the AMA's A26 Informational Reports, highlighting grants, corporate relationships, and public health strategies.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Who should read this
- Regulatory affairs teams
Ask about this report
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Download the full 150-page PDF
Free · 0 B · Instant access after email
The American Medical Association (AMA) A26 Informational Reports for 2025 detail financial activities, corporate relationships, and health initiatives, providing key insights for pharma stakeholders.
Key Takeaways
- Total grants and donations received by the AMA in 2025 amounted to $3,666,000, supporting various public health initiatives.
- The AMA approved 105 corporate activities in 2025, emphasizing collaboration and compliance with established guidelines.
- Key focus areas for the AMA include public health, tobacco control, and Medicare payment reform.
What does this document cover?
The A26 Informational Reports detail the AMA's financial activities, corporate relationships, and updates on various health initiatives for 2025. Specific reports cover grants and donations, corporate relationships, activities in tobacco control, optimal health outcomes, Medicare payment reform, and public health strategy.
Why is this important for pharma teams?
Understanding the AMA's funding sources and strategic initiatives can guide pharmaceutical companies in aligning their business development efforts with public health goals and AMA priorities. The Corporate Review process ensures activities align with AMA Corporate Guidelines.
Frequently Asked Questions
What was the purpose of the Corporate Review process in 2025?
The Corporate Review process, overseen by the Corporate Review Team (CRT), ensures that any activity associating the AMA name or logo with a company or involving commercial support aligns with AMA's corporate relationship principles.
What types of activities are reviewed by the Corporate Review Team?
The CRT reviews a range of activities, including industry-supported projects, AMA sponsorships, licensing programs, member programs, third-party relationships, collaborations with non-profit associations, and collaborations with academic institutions involving corporate sponsorship.
Ready to read the full report?
Join 12,000+ pharma leaders getting deep industry analysis delivered weekly.
Related intelligence
Data First: Enhancing Drug Development with FAIR-by-Design Standards
FAIR-by-design standardization is a necessary investment for maximizing NAM data utility.
Did You Know: Insights from NCPDP's Active Task Groups
NCPDP has 71 active task groups focusing on diverse areas of pharmacy standards.
★ FDA Seeks Input on Drug Repurposing for Unmet Medical Needs
FDA is establishing a public docket for drug repurposing input.